Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Clicks: 174
ID: 273326
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The development of an early exanthema within 6 weeks after treatment start indicates a favorable therapy outcome upon vemurafenib plus cobimetinib. Patients presenting with an early exanthema should therefore be treated with adequate supportive measures to provide that patients can stay on treatment …
Reference Key
kc2021frontiersearly Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kähler KC;Gutzmer R;Meier F;Zimmer L;Heppt M;Gesierich A;Thoms KM;Utikal J;Hassel JC;Loquai C;Pföhler C;Heinzerling L;Kaatz M;Göppner D;Pflugfelder A;Bohne AS;Satzger I;Reinhardt L;Placke JM;Schadendorf D;Ugurel S;;
Journal Frontiers in oncology
Year 2021
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/34109122
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:34109122 pmc8183381 doi:10.3389/fonc.2021.672172 katharina c kähler ralf gutzmer selma ugurel

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.